Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.48 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.48 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19766263 | 0.84 | L3MBTL1 (0.61) | SMN1; SMN2L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL1689404 | 0.81 | HDAC3 (0.62) | HDAC8HDAC3HDAC6P2RX1KCNJ6 | |
| SCHEMBL6483594 | 0.80 | HDAC8 (0.60) | HDAC8HDAC3HDAC6P2RX1KCNJ6 | |
| SCHEMBL4979670 | 0.79 | HDAC8 (0.55) | HDAC8HDAC3HDAC6P2RX1KCNJ6 | |
| SCHEMBL32675964 | 0.79 | RAF1 (0.65) | HDAC8HDAC3HDAC6P2RX1KCNJ6 | |
| SCHEMBL1521780 | 0.79 | HDAC3 (0.52) | HDAC8HDAC3HDAC6P2RX1KCNJ6 | |
| SCHEMBL2093458 | 0.78 | HDAC8 (0.62) | HDAC8HDAC3HDAC6P2RX1KCNJ6 | |
| Bromide SCHEMBL5461571 | 0.78 | HDAC8 (0.54) | HDAC8HDAC3HDAC6P2RX1KCNJ6 | |
| SCHEMBL30695893 | 0.78 | HDAC8 (0.62) | HDAC8HDAC3HDAC6P2RX1KCNJ6 | |
| SCHEMBL2093456 | 0.78 | HDAC8 (0.62) | HDAC8HDAC3HDAC6P2RX1KCNJ6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230303544-A1 | LMO2 PROTEIN INHIBITORS | UNIV OF OXFORD (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | HDAC8 1199/4885HDAC3 1346/4885HDAC6 1192/4885 |
| US-20230303544-A1 | LMO2 PROTEIN INHIBITORS | LMNB2, LMNB1, TPX2 | HDAC8 3885/4885HDAC3 2502/4885HDAC6 2877/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | HDAC8 1199/4885HDAC3 1346/4885HDAC6 1192/4885 |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | HDAC8 1199/4885HDAC3 1346/4885HDAC6 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.